Ultragenyx price target raised to $48 from $47 at Wedbush

Wedbush raised the firm’s price target on Ultragenyx to $48 from $47 and keeps a Neutral rating on the shares. The preannouncement provided by Ultragenyx in January took much of the suspense out of the Q4 financial results update, as all figures provided at the release were consistent, the analyst tells investors in a research note. The firm seeks a more attractive entry point before getting constructive on shares.